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ABSTRACT 
Recombinant Human erythropoietin (RhEpo) has become an important 
discovery in the medical world related to biological products. The 
discovery of RhEpo is very helpful in handling anemia conditions that 
caused by CKD, cancer patients undergoing chemotherapy, HIV and 
patient who lose a lot of blood after surgery. Anemia condition make 
the body cannot produce normally endogenus erythropoietin. 
Erythropoietin helps in proliferation, differentiation and maturation so 
they can increase of normal red blood cells. The erythropoietin gene 
was isolated and produced known as Recombinant Erythropoietin. 
RhEpo has poor stability so the administration still uses the parenteral 
route to preventing aggregation and denaturation. Other developments 
still carried out to optimization the gene of human erythroid cells. This could be an 
apportunity for find targets, drug selection and use of gene therapy for several diseases 
related to another blood disorders. Knowledge regarding the use of RhEpo will be very 
helpful to optimization of therapeutic effects. 
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1. INTRODUCTION 
Human recombinant erythropoietin (RhEpo) has become an important discovery in the 
medical world related to biological products. RhEpo’s research began in 1905 by a professoe 
from Paris with his assistant. They managed to find a hemotropic factor called hemopoietin 
where hemopoietin plays a role in regulating the production of red blood cells. From this 
discovery then continued by subsequent studies that succeeded in finding a hemopoietic 
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substance called ‘erythropoietin gene was carried out by Lin et al and they succeeded in 
proving that this erythropoietin gene was instrument in coding the production of EPO from 
mammalian cells. The erythropoietin gene which wa isolated and produced was later known 




As discussed earlier, this erythropoietin gene works by encoding the EPO gene in the human 
body. EPO helps in the proliferation, differentiation and guarantee the survival of erythroid 
progenito cells so that they can increase and meet the needs of normal red bllod cells. 
Erythropoietin is produced from capillary epithelial cells around the kidney tubules nad by 
liver cells play a role in the production of red cells in the bone marrow. In the condition of 
endogenous eryhtropoietin from the body cannot produce normally then this RhEpo can be 
used to increase the production of red blood cells. As show in Figure 1, simply regulating 
EPo after meeting its receptor will activate homo-dimerazation and phosphorylation requiring 
the STAT/JAK system to be active and move towards the nucleus so as to fix it encoding 





Figure 1. The mechanism of action of erythropoietin. 
 
1.1 Prevalence 
It is known that one of the complications that arise due to CKD is anemia and this occurs in 
about 25% of CKD patients and thus requires blood transfusion. With the discovery of 
Recombinant Human Erythropoietin (RhEpo) is very helpful in handling anemia conditions 
that are not only caused by CKD but some other conditions such as cancer patients udergoing 
chemotherapy, HIV and patients who lose a lot of blood after surgery.
[4,5]
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2. CHARACTERISTICS RHEPO 
RhEpo is produced from Chinese hamster ovary (CHO) cells that have been genetically 
engineered to produce heterogeneous structures similar to the body’s endogenous 
erythropoietin. Erythropoietin is a gycoprotein with a molecular weight of about 30,4 kDa. 
This erythropoietin molecule consists of 2 disulfide bonds to stabilize the amino acid 
polypeptide chain. Chanes in disulfide bonds wills caues a reduction in even loss of 
erythropoietin pharmacological activity (Figure 2). One of the disulfide bonds located 
between positions 7 and 161 has an important role related to the pharmacodynamics of 






Figure 2. Erythropoietin structure. 
 
Erythropoietin has poor stability in water, where erythropoietin will become easily degraded. 
It is also known that in storage using a syringe, erythropoietin absorbs into the syringe wall, 
causing aggregation and denaturation. This aggregation and denaturation can cause serius 
problems because they are irreversible and can cause hypersensitivity reactions.
[8]
 One effort 
to prevent this problem is by using a syringe made from polypropylene which is known from 
the research results does not change the stability of the protein after repacking. In addition it 
can also by the addition of surfactants and amino acids which have a role as erythropoietin 
protectors. Due to the problem of stability in poor water is also finally made erythropoietin 
preparations in the form of dry powder or isotonic solution containing hydrochloric acid/citric 
acid for IV and SC administration.
[4,8]
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3. RECOMBINANT HUMAN ERYTHROPOIETIN (RHEPO) 
3.1 EPO Formulations 
At present many RhEpo preparations have been circulating in the market by using different 
formulations for each factory. From previous studies, RhEpo formulations typically contain 
erythropoietin as active ingredients, mannitol, glycine, leucine, arginine, glutamic acid, tween 
20 and human serum albumin (HSA). One of the RhEpo formulations which contains the 
active ingredient alpha epoietin has the following formulation
[9]
: 
rHuEPO  2000IU 
Polysorbate 80 0.15 mg 
NaCl   2.192 mg 
NaH2PO4.2H2O 0.580 mg 
Na2HPO4.2H2O 1.115 mg 
Glycine  2.50 mg 
Water fro injection to complete 0.5 ml 
 
3.2 Delivery System 
RhEpo administration until now still uses the parenteral route. The study of alternative 
assistance through other channels is still in furteher reseach related to the risk of 
erythropoietin. RhEpo can be given via intravenous and subcutaneous route injection 2-3 
times a coversation tailored to the patient. It can be argued that IV and SC assistance is 
preferable also because of the need for rapid pharmacological action to meet the needs of red 




3.3 Stage of Drug Development 
The development of RhEpo is of concern to many reseacher today, namely finding alternative 
routes other than by parenteral administration, namely through the oral route. Of course thus 
us a big challenge where erythropoietin has poor biovailability, the size of macromolecular 
proteins is also a challenge which is certainly not easy because with a large size it will be 
difficult to penetrate the intestinal epithelial layer and enter the blood vessels. The polymer 
nanocarrier approach is an attempt to overcome this compression through the use of 
polymeric materials it is expected to modulate the release of erythropoietin and encrease its 
absorption in the gastrointestinal tract.
[11] 
 
Other development are also known to have carried out ex vivo optimization efforts to see the 
gene/protein profile of human erythroid cells. This could be an opportunity for the health 
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world to find targets, drug selection and use of gene therapy for several disease related to 





The rapid administration of RhEpo intravenously will experience elimination in normal 
patients due to the very rapid distribution phase by following the rate of first-order kinetics. 
In general, RhEpo bioavailability through the intravenous route is 100% with an elimination 
half-life in the blood circulation of abaout 4-11 hours. Distribution volume is 40-90 mL/kg 
with total clearance of 4-15 mL/hour per kg to reach peak concentration in the blood, 
intravenous administration is faster than subcutaneous administration. Bioavaibility in 
subcutaneous administration ranged from 36-39% with the time reaching peak concentrations 
in the blood aroun 12-18 hours and elimination half-life around 12-18 hours and elimination 
half-life around 24-79 hours. Erythropoietin is dergaded by reticuloendothelial scavenging 
pathways or lymphatic systems.
[13] 
 
Some preparations of RhEpo that are currently available for use include erythropoietin alpha, 






Erythropoietin receptors are protein belonging to the superfamily cytokine reseptor. 
Erythropoietin binding to the erythropoietin receptor triggers homodimerization and 
phosphorylation which then cause the activation of several signal transduction pathways such 
as the JAK2/STAT5 system, G-protein (RAS), calcium channels, and kinases with the 
activation of the JAK/STAT system STAT translocation occurs into the nucleus and attaches 
to the target gene promoter and transcription. Erythropoietin has important activities in 




In clinical use, RhEpo is a mainstay for kidney failure patient with dialysis and not dialysis, 
cancer patient receiving cytostatic drugs such as nonmyeloid malignancy, low-risk 
myelodysplastic syndrome (MDS) and acquired immune deficiency syndrome (AIDS and 
Zidovudine effects).
[12]
 However, side effects are substantial, including hypertention, 
thromboembolism, stroke, and the potential worsening of certain cancers. A single dose over 




C, not in the 
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freezer and must be protected by light. RhEpo is more cost-effectiveness and produces an 
additional cost per QALY around US $18.800.
[13,15] 
 
Table 1: Comparison of varius types of erythropoietin. 




MW (Daltons) 30.000 30.000 37.000 60.000 
Polyethylene glycol 
conjugation 
Absent Absent Absent Present 
Glycosylation sites 3 3 5 - 
Routes of 
administration 
SC, IV, IP SC, IV, IP SC, IV SC, IV 
Half-life (SC 
admn;hours) 
19 20 73 139 
Bioavailability after 
SC administration 










Once a week or 
once in 2 weeks 
Once in 2 weeks to 
once a month 
*SD: Standart Deviation with three replication of treatment 
 
4. CONCLUSION 
The use of RhEpo in the treatment of anemia bocomes very important especially in 
conditions where the production of red blood cells does not occur normally. The clinician’s 
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